{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T04:14:51Z","timestamp":1792124091450,"version":"4.4.0"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"49","license":[{"start":{"date-parts":[[2017,8,21]],"date-time":"2017-08-21T00:00:00Z","timestamp":1503273600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2017,8,21]],"date-time":"2017-08-21T00:00:00Z","timestamp":1503273600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Oncogene"],"published-print":{"date-parts":[[2017,12,7]]},"DOI":"10.1038\/onc.2017.283","type":"journal-article","created":{"date-parts":[[2017,8,21]],"date-time":"2017-08-21T11:00:57Z","timestamp":1503313257000},"page":"6749-6761","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":51,"title":["S100A7: from mechanism to cancer therapy"],"prefix":"10.1038","volume":"36","author":[{"given":"L","family":"Padilla","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Dakhel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"Adan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Masa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J M","family":"Martinez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L","family":"Roque","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T","family":"Coll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R","family":"Hervas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C","family":"Calvis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L","family":"Llinas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Buenestado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"Castellsague","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R","family":"Messeguer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F","family":"Mitjans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J L","family":"Hernandez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,8,21]]},"reference":[{"key":"BFonc2017283_CR1","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/s12916-015-0278-7","volume":"13","author":"F Chen","year":"2015","unstructured":"Chen F, Zhuang X, Lin L, Yu P, Wang Y, Shi Y et al. New horizons in tumor microenvironment biology: challenges and opportunities. BMC Med 2015; 13: 45.","journal-title":"BMC Med"},{"key":"BFonc2017283_CR2","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1038\/nm.3394","volume":"19","author":"DF Quail","year":"2013","unstructured":"Quail DF, Joyce JA . Microenvironmental regulation of tumor progression and metastasis. Nat Med 2013; 19: 1423\u20131437.","journal-title":"Nat Med"},{"key":"BFonc2017283_CR3","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1016\/j.ctrv.2013.11.009","volume":"40","author":"G Limaverde-Sousa","year":"2014","unstructured":"Limaverde-Sousa G, Sternberg C, Ferreira CG . Antiangiogenesis beyond VEGF inhibition: a journey from antiangiogenic single-target to broad-spectrum agents. Cancer Treat Rev 2014; 40: 548\u2013557.","journal-title":"Cancer Treat Rev"},{"key":"BFonc2017283_CR4","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1186\/1478-811X-11-97","volume":"11","author":"CH Heldin","year":"2013","unstructured":"Heldin CH . Targeting the PDGF signaling pathway in tumor treatment. Cell Commun Signal 2013; 11: 97.","journal-title":"Cell Commun Signal"},{"key":"BFonc2017283_CR5","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1097\/JTO.0b013e3182398e69","volume":"7","author":"T Yamada","year":"2012","unstructured":"Yamada T, Takeuchi S, Kita K, Bando H, Nakamura T, Matsumoto K et al. Hepatocyte growth factor induces resistance to anti-epidermal growth factor receptor antibody in lung cancer. J Thorac Oncol 2012; 7: 272\u2013280.","journal-title":"J Thorac Oncol"},{"key":"BFonc2017283_CR6","doi-asserted-by":"publisher","first-page":"24","DOI":"10.2174\/156652413804486214","volume":"13","author":"R Donato","year":"2013","unstructured":"Donato R, Cannon BR, Sorci G, Riuzzi F, Hsu K, Weber DJ et al. Functions of S100 proteins. Curr Mol Med 2013; 13: 24\u201357.","journal-title":"Curr Mol Med"},{"key":"BFonc2017283_CR7","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1038\/nrc3893","volume":"15","author":"AR Bresnick","year":"2015","unstructured":"Bresnick AR, Weber DJ, Zimmer DB . S100 proteins in cancer. Nat Rev Cancer 2015; 15: 96\u2013109.","journal-title":"Nat Rev Cancer"},{"key":"BFonc2017283_CR8","doi-asserted-by":"publisher","first-page":"2706","DOI":"10.1016\/j.bbadis.2015.09.022","volume":"1852","author":"E Leclerc","year":"2015","unstructured":"Leclerc E, Vetter SW . The role of S100 proteins and their receptor RAGE in pancreatic cancer. Biochim Biophys Acta 2015; 1852: 2706\u20132711.","journal-title":"Biochim Biophys Acta"},{"key":"BFonc2017283_CR9","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1016\/j.bbrc.2014.02.143","volume":"446","author":"L Padilla","year":"2014","unstructured":"Padilla L, Dakhel S, Hernandez JL . S100 to receptor for advanced glycation end-products binding assay: looking for inhibitors. Biochem Biophys Res Commun 2014; 446: 404\u2013409.","journal-title":"Biochem Biophys Res Commun"},{"key":"BFonc2017283_CR10","first-page":"89","volume":"4","author":"H Chen","year":"2014","unstructured":"Chen H, Xu C, Jin Q, Liu Z . S100 protein family in human cancer. Am J Cancer Res 2014; 4: 89\u2013115.","journal-title":"Am J Cancer Res"},{"key":"BFonc2017283_CR11","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1593\/neo.121554","volume":"14","author":"J Klingelhofer","year":"2012","unstructured":"Klingelhofer J, Grum-Schwensen B, Beck MK, Knudsen RS, Grigorian M, Lukanidin E et al. Anti-S100A4 antibody suppresses metastasis formation by blocking stroma cell invasion. Neoplasia 2012; 14: 1260\u20131268.","journal-title":"Neoplasia"},{"key":"BFonc2017283_CR12","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1097\/PPO.0b013e31827e0b86","volume":"19","author":"MT Schweizer","year":"2013","unstructured":"Schweizer MT, Carducci MA . From bevacizumab to tasquinimod: angiogenesis as a therapeutic target in prostate cancer. Cancer J 2013; 19: 99\u2013106.","journal-title":"Cancer J"},{"key":"BFonc2017283_CR13","doi-asserted-by":"publisher","first-page":"e72480","DOI":"10.1371\/journal.pone.0072480","volume":"8","author":"JL Hernandez","year":"2013","unstructured":"Hernandez JL, Padilla L, Dakhel S, Coll T, Hervas R, Adan J et al. Therapeutic targeting of tumor growth and angiogenesis with a novel anti-S100A4 monoclonal antibody. PLoS One 2013; 8: e72480.","journal-title":"PLoS One"},{"key":"BFonc2017283_CR14","doi-asserted-by":"publisher","first-page":"e92","DOI":"10.1038\/oncsis.2014.7","volume":"3","author":"S Dakhel","year":"2014","unstructured":"Dakhel S, Padilla L, Adan J, Masa M, Martinez JM, Roque L et al. S100P antibody-mediated therapy as a new promising strategy for the treatment of pancreatic cancer. Oncogenesis 2014; 3: e92.","journal-title":"Oncogenesis"},{"key":"BFonc2017283_CR15","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.lungcan.2007.02.020","volume":"57","author":"H Zhang","year":"2007","unstructured":"Zhang H, Wang Y, Chen Y, Sun S, Li N, Lv D et al. Identification and validation of S100A7 associated with lung squamous cell carcinoma metastasis to brain. Lung Cancer 2007; 57: 37\u201345.","journal-title":"Lung Cancer"},{"key":"BFonc2017283_CR16","doi-asserted-by":"publisher","first-page":"2057","DOI":"10.1016\/S0002-9440(10)65524-1","volume":"155","author":"S Al-Haddad","year":"1999","unstructured":"Al-Haddad S, Zhang Z, Leygue E, Snell L, Huang A, Niu Y et al. Psoriasin (S100A7) expression and invasive breast cancer. Am J Pathol 1999; 155: 2057\u20132066.","journal-title":"Am J Pathol"},{"key":"BFonc2017283_CR17","doi-asserted-by":"publisher","first-page":"e11939","DOI":"10.1371\/journal.pone.0011939","volume":"5","author":"SC Tripathi","year":"2010","unstructured":"Tripathi SC, Matta A, Kaur J, Grigull J, Chauhan SS, Thakar A et al. Nuclear S100A7 is associated with poor prognosis in head and neck cancer. PLoS One 2010; 5: e11939.","journal-title":"PLoS One"},{"key":"BFonc2017283_CR18","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.4049\/jimmunol.181.2.1499","volume":"181","author":"R Wolf","year":"2008","unstructured":"Wolf R, Howard OM, Dong HF, Voscopoulos C, Boeshans K, Winston J et al. Chemotactic activity of S100A7 (Psoriasin) is mediated by the receptor for advanced glycation end products and potentiates inflammation with highly homologous but functionally distinct S100A15. J Immunol 2008; 181: 1499\u20131506.","journal-title":"J Immunol"},{"key":"BFonc2017283_CR19","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.3892\/ol.2012.612","volume":"3","author":"K Kataoka","year":"2012","unstructured":"Kataoka K, Ono T, Murata H, Morishita M, Yamamoto KI, Sakaguchi M et al. S100A7 promotes the migration and invasion of osteosarcoma cells via the receptor for advanced glycation end products. Oncol Lett 2012; 3: 1149\u20131153.","journal-title":"Oncol Lett"},{"key":"BFonc2017283_CR20","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1007\/s10549-011-1920-5","volume":"134","author":"E Shubbar","year":"2012","unstructured":"Shubbar E, Vegfors J, Carlstrom M, Petersson S, Enerback C . Psoriasin (S100A7) increases the expression of ROS and VEGF and acts through RAGE to promote endothelial cell proliferation. Breast Cancer Res Treat 2012; 134: 71\u201380.","journal-title":"Breast Cancer Res Treat"},{"key":"BFonc2017283_CR21","first-page":"2627","volume":"9","author":"ED Emberley","year":"2003","unstructured":"Emberley ED, Niu Y, Njue C, Kliewer EV, Murphy LC, Watson PH . Psoriasin (S100A7) expression is associated with poor outcome in estrogen receptor-negative invasive breast cancer. Clin Cancer Res 2003; 9: 2627\u20132631.","journal-title":"Clin Cancer Res"},{"key":"BFonc2017283_CR22","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1158\/0008-5472.CAN-11-0669","volume":"72","author":"MW Nasser","year":"2012","unstructured":"Nasser MW, Qamri Z, Deol YS, Ravi J, Powell CA, Trikha P et al. S100A7 enhances mammary tumorigenesis through upregulation of inflammatory pathways. Cancer Res 2012; 72: 604\u2013615.","journal-title":"Cancer Res"},{"key":"BFonc2017283_CR23","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1158\/0008-5472.CAN-14-2161","volume":"75","author":"MW Nasser","year":"2015","unstructured":"Nasser MW, Wani NA, Ahirwar DK, Powell CA, Ravi J, Elbaz M et al. RAGE mediates S100A7-induced breast cancer growth and metastasis by modulating the tumor microenvironment. Cancer Res 2015; 75: 974\u2013985.","journal-title":"Cancer Res"},{"key":"BFonc2017283_CR24","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1111\/1523-1747.ep12294284","volume":"107","author":"T Jinquan","year":"1996","unstructured":"Jinquan T, Vorum H, Larsen CG, Madsen P, Rasmussen HH, Gesser B et al. Psoriasin: a novel chemotactic protein. J Invest Dermatol 1996; 107: 5\u201310.","journal-title":"J Invest Dermatol"},{"key":"BFonc2017283_CR25","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1038\/256495a0","volume":"256","author":"G Kohler","year":"1975","unstructured":"Kohler G, Milstein C . Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 1975; 256: 495\u2013497.","journal-title":"Nature"},{"key":"BFonc2017283_CR26","doi-asserted-by":"publisher","first-page":"3658","DOI":"10.1074\/jbc.M102950200","volume":"277","author":"MJ Robinson","year":"2002","unstructured":"Robinson MJ, Tessier P, Poulsom R, Hogg N . The S100 family heterodimer, MRP-8\/14, binds with high affinity to heparin and heparan sulfate glycosaminoglycans on endothelial cells. J Biol Chem 2002; 277: 3658\u20133665.","journal-title":"J Biol Chem"},{"key":"BFonc2017283_CR27","doi-asserted-by":"publisher","first-page":"e19375","DOI":"10.1371\/journal.pone.0019375","volume":"6","author":"Q Jin","year":"2011","unstructured":"Jin Q, Chen H, Luo A, Ding F, Liu Z . S100A14 stimulates cell proliferation and induces cell apoptosis at different concentrations via receptor for advanced glycation end products (RAGE). PLoS One 2011; 6: e19375.","journal-title":"PLoS One"},{"key":"BFonc2017283_CR28","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1002\/jcp.10462","volume":"199","author":"G Sorci","year":"2004","unstructured":"Sorci G, Riuzzi F, Agneletti AL, Marchetti C, Donato R . S100B causes apoptosis in a myoblast cell line in a RAGE-independent manner. J Cell Physiol 2004; 199: 274\u2013283.","journal-title":"J Cell Physiol"},{"key":"BFonc2017283_CR29","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1111\/bjd.14718","volume":"175","author":"J Vegfors","year":"2016","unstructured":"Vegfors J, Ekman AK, Stoll SW, Bivik Eding C, Enerback C . Psoriasin (S100A7) promotes stress-induced angiogenesis. Br J Dermatol 2016; 175: 1263\u20131273.","journal-title":"Br J Dermatol"},{"key":"BFonc2017283_CR30","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1046\/j.1365-2567.1999.00867.x","volume":"98","author":"KC McCullough","year":"1999","unstructured":"McCullough KC, Basta S, Knotig S, Gerber H, Schaffner R, Kim YB et al. Intermediate stages in monocyte-macrophage differentiation modulate phenotype and susceptibility to virus infection. Immunology 1999; 98: 203\u2013212.","journal-title":"Immunology"},{"key":"BFonc2017283_CR31","doi-asserted-by":"publisher","first-page":"e75328","DOI":"10.1371\/journal.pone.0075328","volume":"8","author":"Q Peng","year":"2013","unstructured":"Peng Q, Cai H, Sun X, Li X, Mo Z, Shi J . Alocasia cucullata exhibits strong antitumor effect in vivo by activating antitumor immunity. PLoS One 2013; 8: e75328.","journal-title":"PLoS One"},{"key":"BFonc2017283_CR32","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.canlet.2013.10.036","volume":"344","author":"IJ Bettum","year":"2014","unstructured":"Bettum IJ, Vasiliauskaite K, Nygaard V, Clancy T, Pettersen SJ, Tenstad E et al. Metastasis-associated protein S100A4 induces a network of inflammatory cytokines that activate stromal cells to acquire pro-tumorigenic properties. Cancer Lett 2014; 344: 28\u201339.","journal-title":"Cancer Lett"},{"key":"BFonc2017283_CR33","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1136\/thx.2007.087015","volume":"63","author":"H Zhang","year":"2008","unstructured":"Zhang H, Zhao Q, Chen Y, Wang Y, Gao S, Mao Y et al. Selective expression of S100A7 in lung squamous cell carcinomas and large cell carcinomas but not in adenocarcinomas and small cell carcinomas. Thorax 2008; 63: 352\u2013359.","journal-title":"Thorax"},{"key":"BFonc2017283_CR34","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1007\/s00726-010-0822-x","volume":"41","author":"S Wolf","year":"2011","unstructured":"Wolf S, Haase-Kohn C, Lenk J, Hoppmann S, Bergmann R, Steinbach J et al. Expression, purification and fluorine-18 radiolabeling of recombinant S100A4: a potential probe for molecular imaging of receptor for advanced glycation endproducts in vivo? Amino Acids 2011; 41: 809\u2013820.","journal-title":"Amino Acids"},{"key":"BFonc2017283_CR35","first-page":"7","volume":"22","author":"L Rich","year":"2005","unstructured":"Rich L, Whittaker P . Collagen and picrosirius red staining: a polarized light assessment of fibrillar hue and spatial distribution. Braz J Morphol Sci 2005; 22: 7.","journal-title":"Braz J Morphol Sci"},{"key":"BFonc2017283_CR36","doi-asserted-by":"publisher","first-page":"20130676","DOI":"10.1259\/bjr.20130676","volume":"87","author":"SR McKeown","year":"2014","unstructured":"McKeown SR . Defining normoxia, physoxia and hypoxia in tumours-implications for treatment response. Br J Radiol 2014; 87: 20130676.","journal-title":"Br J Radiol"},{"key":"BFonc2017283_CR37","doi-asserted-by":"publisher","first-page":"2083","DOI":"10.1038\/onc.2009.488","volume":"29","author":"NR West","year":"2010","unstructured":"West NR, Watson PH . S100A7 (psoriasin) is induced by the proinflammatory cytokines oncostatin-M and interleukin-6 in human breast cancer. Oncogene 2010; 29: 2083\u20132092.","journal-title":"Oncogene"},{"key":"BFonc2017283_CR38","doi-asserted-by":"publisher","first-page":"11326","DOI":"10.1158\/0008-5472.CAN-05-1523","volume":"65","author":"I Krop","year":"2005","unstructured":"Krop I, Marz A, Carlsson H, Li X, Bloushtain-Qimron N, Hu M et al. A putative role for psoriasin in breast tumor progression. Cancer Res 2005; 65: 11326\u201311334.","journal-title":"Cancer Res"},{"key":"BFonc2017283_CR39","first-page":"1954","volume":"63","author":"ED Emberley","year":"2003","unstructured":"Emberley ED, Niu Y, Leygue E, Tomes L, Gietz RD, Murphy LC et al. Psoriasin interacts with Jab1 and influences breast cancer progression. Cancer Res 2003; 63: 1954\u20131961.","journal-title":"Cancer Res"},{"key":"BFonc2017283_CR40","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/j.jhep.2014.07.035","volume":"62","author":"L Chen","year":"2014","unstructured":"Chen L, Li J, Zhang J, Dai C, Liu X, Wang J et al. S100A4 promotes liver fibrosis via activation of hepatic stellate cells. J Hepatol 2014; 62: 156\u2013164.","journal-title":"J Hepatol"},{"key":"BFonc2017283_CR41","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s12935-016-0374-6","volume":"17","author":"SH Choi","year":"2017","unstructured":"Choi SH, Park JY . Regulation of the hypoxic tumor environment in hepatocellular carcinoma using RNA interference. Cancer Cell Int 2017; 17: 3.","journal-title":"Cancer Cell Int"},{"key":"BFonc2017283_CR42","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1158\/2159-8290.CD-13-0199","volume":"4","author":"L Moserle","year":"2014","unstructured":"Moserle L, Jimenez-Valerio G, Casanovas O . Antiangiogenic therapies: going beyond their limits. Cancer Discov 2014; 4: 31\u201341.","journal-title":"Cancer Discov"},{"key":"BFonc2017283_CR43","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1194\/jlr.M500555-JLR200","volume":"47","author":"J Huber","year":"2006","unstructured":"Huber J, Furnkranz A, Bochkov VN, Patricia MK, Lee H, Hedrick CC et al. Specific monocyte adhesion to endothelial cells induced by oxidized phospholipids involves activation of cPLA2 and lipoxygenase. J Lipid Res 2006; 47: 1054\u20131062.","journal-title":"J Lipid Res"},{"key":"BFonc2017283_CR44","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1007\/BF01002772","volume":"11","author":"LC Junqueira","year":"1979","unstructured":"Junqueira LC, Bignolas G, Brentani RR . Picrosirius staining plus polarization microscopy, a specific method for collagen detection in tissue sections. Histochem J 1979; 11: 447\u2013455.","journal-title":"Histochem J"},{"key":"BFonc2017283_CR45","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1172\/JCI8768","volume":"106","author":"A Ducharme","year":"2000","unstructured":"Ducharme A, Frantz S, Aikawa M, Rabkin E, Lindsey M, Rohde LE et al. Targeted deletion of matrix metalloproteinase-9 attenuates left ventricular enlargement and collagen accumulation after experimental myocardial infarction. J Clin Invest 2000; 106: 55\u201362.","journal-title":"J Clin Invest"},{"key":"BFonc2017283_CR46","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1016\/j.molonc.2012.04.003","volume":"6","author":"AV Laenkholm","year":"2012","unstructured":"Laenkholm AV, Knoop A, Ejlertsen B, Rudbeck T, Jensen MB, Muller S et al. ESR1 gene status correlates with estrogen receptor protein levels measured by ligand binding assay and immunohistochemistry. Mol Oncol 2012; 6: 428\u2013436.","journal-title":"Mol Oncol"}],"container-title":["Oncogene"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/onc2017283.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/onc2017283","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/doifinder\/10.1038\/onc.2017.283","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/www.nature.com\/articles\/onc2017283.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,21]],"date-time":"2022-03-21T16:07:37Z","timestamp":1647878857000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/onc2017283"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8,21]]},"references-count":46,"journal-issue":{"issue":"49","published-print":{"date-parts":[[2017,12,7]]}},"alternative-id":["BFonc2017283"],"URL":"https:\/\/doi.org\/10.1038\/onc.2017.283","relation":{},"ISSN":["0950-9232","1476-5594"],"issn-type":[{"value":"0950-9232","type":"print"},{"value":"1476-5594","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,8,21]]},"assertion":[{"value":"17 January 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 June 2017","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 July 2017","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 August 2017","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}